FDA Approves Kresladi Gene Therapy for Rare Immune Disorder

The U.S. Food and Drug Administration (FDA) has approved Kresladi, a groundbreaking gene therapy designed to treat severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder that leads to recurrent life-threatening infections. This approval marks a significant milestone in pediatric medicine, especially for conditions with limited treatment options. Developed following a clinical trial at UCLA, led by Dr. Donald Kohn, the therapy demonstrated that all nine children involved in the trial survived without needing bone marrow transplants. The successful outcomes from this trial underscore the potential of gene therapy as a viable treatment for severe immune disorders.

Severe leukocyte adhesion deficiency-I is a rare condition affecting approximately one in one million children worldwide. It stems from mutations in the ITGB2 gene, which are essential for the proper functioning of white blood cells. These mutations impede immune cells' ability to reach infection sites, resulting in recurrent and often severe bacterial and fungal infections. Historically, children with this condition faced poor survival rates beyond childhood without effective treatment options. The approval of Kresladi represents a significant advancement in managing this rare disorder.

The clinical trial that led to Kresladi's approval involved nine patients aged between 5 months and 9 years, highlighting the rarity of LAD-I. The trial was a collaborative effort between UCLA and Rocket Pharmaceuticals, which sponsored the study. Six patients were treated at UCLA, while the remaining three received treatment in London and Spain. This one-time gene therapy utilizes the child’s own blood stem cells, incorporating a healthy copy of the ITGB2 gene before reintroducing these modified cells back into the patient. This approach reduces the risk of immune rejection, a common issue with donor cell transplants.

The benefits of Kresladi extend beyond its immediate therapeutic effects. All nine patients in the trial avoided the need for bone marrow transplants, which typically carry significant risks and complications, including extensive chemotherapy. The therapy demonstrated a marked reduction in the incidence of severe infections that required hospitalization. Additionally, researchers noted improvements in white blood cell counts and sustained expression of the therapeutic gene, indicating long-lasting benefits for the children involved.

Looking ahead, the FDA's approval of Kresladi is expected to foster further advancements in gene therapy for rare diseases. Dr. Kohn is optimistic that this milestone will encourage more pharmaceutical companies to invest in developing treatments for other rare genetic disorders. He is currently conducting trials for a treatment targeting another critical immune disorder, ADA-SCID. The success of Kresladi could act as a catalyst for additional research and funding, ultimately enhancing the availability of innovative therapies for patients with rare diseases.